SCHEMBL359600

SCHEMBL359600

Clc1ncncc1I

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2329711 0.97
SCHEMBL4451404 0.80 CHEK1 (0.34)
SCHEMBL691236 0.72
Ammonia Solution, Strong SCHEMBL28196082 0.70
Hydrochloric Acid SCHEMBL1937524 0.70
SCHEMBL22317823 0.69 CSNK2A1 (0.32)
SCHEMBL29421577 0.69 CSNK2A1 (0.32)
SCHEMBL25402182 0.68
SCHEMBL14757658 0.68
SCHEMBL13261991 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024110863-A1 PROCESS AND INTERMEDIATES FOR PREPARING ((1R,2S,4R)-4-((5-(4-((R)-7-CHLORO-1,2,3,4-TETRAHYDROISOQUINOLIN-1-YL)-5-METHYLTHIOPHENE-2-CARBONYL)PYRIMIDIN-4-YL)AMINO)-2-HYDROXYCYCLOPENTYL)METHYL SULFAMATE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-05-30 WO claimed
US-20260132158-A1 PHENYL OXY AMIDE KINASE INHIBITORS THE TRANSLATIONAL GENOMICS RESEARCH INST (US) 2026-05-14 US disclosed
US-12577228-B2 Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds UCB Biopharma SRL (BE) 2026-03-17 US disclosed
EP-4081296-B1 DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS UCB Biopharma SRL (BE) 2026-02-11 EP disclosed
WO-2025264532-A1 DIHYDROPYRIMIDOPYRIMIDINES TESSEL BIOSCIENCES, INC. (US) 2025-12-26 WO disclosed
US-20250382304-A1 HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS NUVALENT INC (US) 2025-12-18 US disclosed
EP-4661966-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF Type6 Therapeutics, Inc. (US) 2025-12-17 EP disclosed
US-12497382-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2025-12-16 US disclosed
US-20250353853-A1 FLAVIVIRUS INHIBITORS IRBM S.P.A. (IT) 2025-11-20 US disclosed
US-20250326764-A1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS LLC (US) 2025-10-23 US disclosed
US-6492372-B1 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 ELAN PHARMACEUTICALS, INC. 2002-12-10 US disclosed
EP-1224183-A2 HETEROCYCLIC SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD BRISTOL-MYERS SQUIBB COMPANY (US) 2002-07-24 EP disclosed
CN-1351592-A Acyl derivatives for the treatment of VLA-4 related diseases ELAN PHARM INC (US) 2002-05-29 CN disclosed
US-20020052375-A1 3-(Heteroaryal) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) 2002-05-02 US disclosed
WO-2002008203-A2 3-(HETEROARYL) ALANINE DERIVATIVES-INHIBITORS OF LEUKOCYTE ADHESION MEDIATED BY VLA-4 ELAN PHARMACEUTICALS, INC. (US) 2002-01-31 WO disclosed
WO-2002008205-A1 SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY KRENITSKY PHARMACEUTICALS, INC. (US) 2002-01-31 WO disclosed
EP-1144388-A1 ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS Elan Pharmaceuticals, Inc. (US) 2001-10-17 EP disclosed
WO-2001027107-A2 HETEROCYCLIC SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD BRISTOL-MYERS SQUIBB COMPANY (US) 2001-04-19 WO disclosed
WO-2000043372-A1 ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS ELAN PHARMACEUTICALS, INC. (US) 2000-07-27 WO disclosed
CN-1259948-A 6,7-disubstituted-4-aminopyrido [2,3-D] pyrimidine compounds ABBOTT LAB (US) 2000-07-12 CN disclosed